UOC
AEON icon

UBS O'Connor’s AEON Biopharma AEON Stock Holding History

UBS O'Connor’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-6,601
Closed -$4.68M – 23
2022
Q3 		$4.68M Sell
6,601
-663
-9% -$470K 0.05% 297
2022
Q2 		$5.13M Buy
+7,264
New +$5.13M 0.05% 289
2022
Q1 		– Sell
-7,136
Closed -$4.99M – 13
2021
Q4 		$4.99M Buy
7,136
+192
+3% +$135K 0.05% 284
2021
Q3 		$4.88M Hold
6,944
– – 0.04% 293
2021
Q2 		$4.82M Buy
+6,944
New +$4.85M 0.04% 288

Other funds holding AEON

ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

UBS O'Connor's AEON Position: Q4 2022 in Review

UBS O'Connor sold out of AEON Biopharma (AEON) in Q4 2022, closing a stake of 6,601 shares — an estimated $4.68M sold.

UBS O'Connor first reported a position in AEON in Q2 2021 and held it in 5 quarters. The position peaked at $5.13M in Q2 2022. 85 funds tracked by Wall St. Rank hold AEON as of Q4 2022.

  • UBS O'Connor reported no remaining AEON Biopharma position as of Q4 2022 after selling out during the quarter.
  • UBS O'Connor sold 6,601 AEON Biopharma shares in Q4 2022, an estimated $4.68M.
  • UBS O'Connor first reported a position in AEON Biopharma in Q2 2021 and held it in 5 quarters.
  • UBS O'Connor's AEON Biopharma position peaked at $5.13M in Q2 2022.
  • 85 funds tracked by Wall St. Rank held AEON Biopharma as of Q4 2022.

Based on UBS O'Connor's 13F filing for Q4 2022, filed 14 Feb 2023.